shaping the future of drug development · base - super superiority mams - binomial multi-stage;...
TRANSCRIPT
![Page 1: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/1.jpg)
What's New in East 6.5? MCPMod,
Population Enrichment, & Program-Level Design
Pantelis Vlachos, PhD [email protected]
Charles Liu, PhD
Shaping the Future of Drug Development
![Page 2: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/2.jpg)
Agenda
• East: From 6.4 to 6.5 • New modules, the methods
• MCPMod • Population Enrichment • Program-Level Design
• Demo • Further enhancements in East 6.5 • Q&A
2
![Page 3: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/3.jpg)
BASE
MULTIARM
ENDPOINTS
EXACT
ESCALATE
SEQUENTIAL
ADAPT
SURVIVAL SURVADAPT
PREDICT
MAMS
East 6.4
3
![Page 4: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/4.jpg)
BASE
MULTIARM
ENDPOINTS
EXACT
ESCALATE
SEQUENTIAL
ADAPT
SURVIVAL SURVADAPT
PREDICT
MAMS
East 6.5 (three new modules)
MCPMod Pop Enrichment
Program Design 4
![Page 5: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/5.jpg)
Dose-response studies
Establish Proof-of-Concept (PoC) • change in dose desirable change
in endpoint of interest
Dose finding step • Select one (or more) “good” dose levels
for confirmatory Phase III once PoC has been established
5
![Page 6: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/6.jpg)
Traditional Approach
Proof-of-Concept: Conducted using (multiple) active arms and placebo
Selection of Target Dose:
1. statistically significant at the proof-of-concept stage 2. smallest of statistically significant doses but also
clinically relevant
Dose-Response Modeling: 1. use data from PoC and earlier trials 2. find a statistical model capturing the effects of
target dose on dose-response
6
![Page 7: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/7.jpg)
Traditional Approach
Straight-forward approach However:
• focuses on narrow dose range where sponsors can have faith that they will establish a clear dose-signal
• dose-response model should itself play a greater role in choosing the right dose
• focuses on modeling at the very end of the process
7
![Page 8: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/8.jpg)
MCP vs Mod
MCP: • Dose is a qualitative factor • Inference about target dose restricted to the
discrete set of doses used in the trial
Mod: Dose Response (parametric functional relationship) • Dose is quantitative • Modeling approach validity depends on pre-
specification of appropriate dose-response model
8
![Page 9: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/9.jpg)
MCP + Mod = MCPMod
• Design stage • Pre-specification of
candidate dose-response models
• Analysis stage (MCP-step) • Statistical test for dose-
response signal. Model selection based on significant dose response models
• Analysis stage (Mod-step) • Dose response and
target dose estimation based on dose-response modeling
9
![Page 10: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/10.jpg)
At the end
MCP-Mod • Combines multiple comparison and model
based approaches • Robust to model misspecification • Flexible dose estimation
Result • More informative phase 2 designs, more solid
basis for confirmatory study!
Endorsed by EMA and FDA!
10
![Page 11: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/11.jpg)
MCPMod
For analysis, Cytel’s Proc MCPMod already available on SAS platform
East 6.5 module will include analysis and design (sample
size / power, individually for each candidate model, and summarized)
Design can be based on Optimal Allocation Available for Normal, Binary and Count endpoints
11
![Page 12: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/12.jpg)
Angiosarcoma is an ultraorphan disease Poorly addressed by current treatments
• Pazopanib a VEGF inhibitor shows modest benefit • TRC105 can compliment Pazopanib by inhibiting
endoglin, a different angiogenic target Adaptive trial considered optimal due to:
• Small population (1800 cases/year) • Limited prior data • Subgroup interaction. Greater benefit possible
with TRC105 for cutaneous vs visceral tumors
Adaptive population enrichment: Motivating example
12
![Page 13: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/13.jpg)
p1: p-value for data from cohort 1 p2: p-value for data from cohort 2
2-Stage Design with SSR and Enrichment
All
Comers
Interi
m
Analysis
Favorable: Continue as planned
Promising: Increase sample size
Unfavorable Continue as planned
Enrich with cutaneous subgroup
TRC105 +Pazopanib
Pazopanib
Stop for futility
13
![Page 14: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/14.jpg)
In case of no enrichment, declare significance on Full population if 𝑤↓1 Φ↑−1 (𝑝↓1↑𝐹𝑆 )+ 𝑤↓2 Φ↑−1 (𝑝↓2↑𝐹𝑆 )> 𝑧↓𝛼 𝑤↓1 Φ↑−1 (𝑝↓1↑𝐹 )+ 𝑤↓2 Φ↑−1 (𝑝↓2↑𝐹 )> 𝑧↓𝛼
In case of enrichment, declare
significance on cutaneous subgroup if 𝑤↓1 Φ↑−1 (𝑝↓1↑𝐹𝑆 )+ 𝑤↓2 Φ↑−1 (𝑝↓2↑𝑆 )> 𝑧↓𝛼 𝑤↓1 Φ↑−1 (𝑝↓1↑𝑆 )+ 𝑤↓2 Φ↑−1 (𝑝↓2↑𝑆 )> 𝑧↓𝛼
Closed testing with combination of p-values
14
![Page 15: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/15.jpg)
Independence of p1 and p2 essential for valid level-α test Use of auxiliary data in the censored observations of
cohort 1 that become completers in cohort 2 is forbidden • ORR data, lab values, toxicities of patients censored for PFS in
cohort 1 can provide insights about their eventual PFS result in cohort 2
But use of auxiliary data to decide on enrichment
destroys independence of p1 and p2
(Jenkins, Stone and Jennison, Pharmaceutical Statistics, 2011)
Special Challenge of Time-to-Event Endpoint
15
![Page 16: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/16.jpg)
Do not choose the interim analysis time point to split data into cohort 1 and cohort 2
Instead, pre-specify allocation of events and sample
size to each cohort before taking the interim analysis • 70 patients and 60 events for cohort 1 • 54 patients and 35 events for cohort 2 • Interim analysis after 40 events have arrived
That will permit full inspection of all cohort 1 data at interim analysis, including censored data
How to permit use of auxiliary data
16
![Page 17: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/17.jpg)
In the end…
17
![Page 18: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/18.jpg)
Program Design Design and simulate sequence of trials Two types planned for 6.5:
• Dose Escalation followed by a cohort expansion study o Stage1: Dose escalation design (3+3, mTPI, CRM, BLRM) o Stage2: Single-arm cohort expansion o Frequentist or Bayesian GNG rules
• Phase 2 oncology trial followed by Group Sequential o Stage1: Single-arm binomial, Simon’s two-stage, or 2-arm
survival o Stage2: A group sequential design
18
![Page 19: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/19.jpg)
As Sponsor was preparing Early Development Plan, posed these questions:
• How can the relationship between early biomarkers and clinical endpoints be leveraged to optimize Phase 1 - 2 plans? (improve quality of information or speed development time) o How can different designs for Ph1b (PoC and Dose-
Finding with biomarkers) improve design of Ph2b? o Can we use Ph1b data to optimize dose selection
for a Ph2b study, allowing reduced Ph2b sample size and/or improved chance of picking correct Ph3 dose?
Program Design: Motivation
19
![Page 20: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/20.jpg)
Initial Ph1b-Ph2b Development Plan
Go
Ph1b Biomarker
Dose- Finding
Ph1b Biomarker
PoC
Go
Ph2b with Clinical
Endpoint
Go
STOP
STOP
STOP
Ph3
Key Objective Design Ph2b trial to maximize probability of Ph3 dose choice
20
![Page 21: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/21.jpg)
Define true underlying scenario(s) for endpoint(s), study design(s), decision rule(s)
Generate many repetitions Summarize results Use to choose and justify trial design - Demonstrates design performance for a
span of potential true scenarios Widely used in Drug Development
Clinical Trial Simulation
21
![Page 22: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/22.jpg)
Define a sequence of clinical trial simulations and decision rules and design options for moving from one trial to the next
Aim to optimize the sequence of trials for a particular set of drug program objectives
Drug Program Simulation
22
![Page 23: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/23.jpg)
In the end…
23
![Page 24: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/24.jpg)
Up next: New module examples
Shaping the Future of Drug Development
![Page 25: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/25.jpg)
MCPMod example
25
![Page 26: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/26.jpg)
MCPMod example
26
![Page 27: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/27.jpg)
MCPMod example
27
![Page 28: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/28.jpg)
MCPMod example
28
![Page 29: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/29.jpg)
MCPMod example
29
![Page 30: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/30.jpg)
MCPMod example
30
![Page 31: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/31.jpg)
MCPMod example
31
![Page 32: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/32.jpg)
Population Enrichment example
32
![Page 33: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/33.jpg)
Population Enrichment example
33
![Page 34: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/34.jpg)
Population Enrichment example
34
![Page 35: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/35.jpg)
Population Enrichment example
35
![Page 36: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/36.jpg)
Population Enrichment example
36
![Page 37: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/37.jpg)
Program Design example
37
![Page 38: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/38.jpg)
Program Design example
38
![Page 39: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/39.jpg)
Program Design example
39
![Page 40: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/40.jpg)
Program Design example
40
![Page 41: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/41.jpg)
Program Design example
41
![Page 42: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/42.jpg)
Program Design example
42
![Page 43: Shaping the Future of Drug Development · BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination SEQUENTIAL – Equivalence Group Sequential ADAPT/SURVADAPT](https://reader033.vdocuments.net/reader033/viewer/2022050506/5f97e801b7df5e133a6b8a3c/html5/thumbnails/43.jpg)
Further Enhancements in East 6.5
BASE - Super Superiority MAMS - Binomial multi-stage; Survival p-value combination
SEQUENTIAL – Equivalence Group Sequential
ADAPT/SURVADAPT - SSR for Non-Inferiority designs
PREDICT – Weibull distribution
ESCALATE - mTPI-2
MEP - Mixed endpoint type; gMCP
43